LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Aandelen Lijst・Kura Oncology Inc

Kura Oncology Inc

Gesloten

SectorGezondheidszorg

9.41 0.86

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

9.31

Max

9.5

Belangrijke statistieken
By Trading Economics
Inkomsten	-6.9M -81M
Verkoop	-3.4M 17M
Winstmarge	-467.23
Werknemers	260
EBITDA	-12M -86M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+201.82% upside

Dividenden
By Dow Jones
Volgende Winsten	12 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	66M 821M
Vorige openingsprijs	8.55
Vorige sluitingsprijs	9.41

Nieuwssentiment

By Acuity

50%

192 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

5.575 / 6.6 Steun & Weerstand

Kura Oncology Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

8 mei 2026, 23:55 UTC

Winsten

Review & Preview: Still Going Strong -- Barrons.com

8 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 mei 2026, 20:49 UTC

Winsten

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 mei 2026, 20:25 UTC

Winsten

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mei 2026, 19:43 UTC

Winsten

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 mei 2026, 19:43 UTC

Winsten

Cencosud 1Q Net $115M

8 mei 2026, 19:20 UTC

Marktinformatie

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 mei 2026, 19:18 UTC

Winsten

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 mei 2026, 19:16 UTC

Winsten

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mei 2026, 19:08 UTC

Winsten

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 mei 2026, 19:05 UTC

Winsten

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 mei 2026, 19:02 UTC

Marktinformatie

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 mei 2026, 18:51 UTC

Winsten

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 mei 2026, 18:49 UTC

Winsten

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 mei 2026, 18:41 UTC

Winsten

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 mei 2026, 17:38 UTC

Marktinformatie

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 mei 2026, 17:14 UTC

Winsten

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 mei 2026, 17:04 UTC

Marktinformatie

Zcash Caps Off Parabolic Week -- Market Talk

8 mei 2026, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

8 mei 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

8 mei 2026, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

8 mei 2026, 15:39 UTC

Marktinformatie

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 mei 2026, 15:39 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

8 mei 2026, 15:39 UTC

Marktinformatie

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 mei 2026, 15:36 UTC

Marktinformatie

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 mei 2026, 15:20 UTC

Marktinformatie

'Altcoin Season' Indicator on the Rise -- Market Talk

8 mei 2026, 15:20 UTC

Marktinformatie

Winsten

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 mei 2026, 15:05 UTC

Marktinformatie

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 mei 2026, 14:42 UTC

Marktinformatie

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 mei 2026, 14:39 UTC

Marktinformatie

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Peer Vergelijking

Prijswijziging

Kura Oncology Inc Prognose

Koersdoel

By TipRanks

201.82% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 28.13 USD 201.82%

Hoogste 40 USD

Laagste 15 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Kura Oncology Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Kura Oncology Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

5.575 / 6.6Steun & Weerstand

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Sentiment

By Acuity

192 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.